Breast imaging device developer Imaging Diagnostic Systems has received an order for its CT Laser Mammography system (CTLM), a work-in-progress device that uses infrared laser light to image breast tissue. The company signed an agreement at the RSNA show
Breast imaging device developer Imaging Diagnostic Systems has received an order for its CT Laser Mammography system (CTLM), a work-in-progress device that uses infrared laser light to image breast tissue. The company signed an agreement at the RSNA show last month with Cycle of Life Technologies of Toronto for two of the units. The deal should bring in approximately $500,000, the first revenues generated by the Fort Lauderdale, FL, firm since it was established. IDSI expects to deliver the devices during the first quarter of next year.
The agreement also covers the delivery of two more CTLM devices once the first order has been fulfilled, as well as a distribution contract for 50 systems over the next two years. Cycle of Life Technologies supplies medical services and equipment to clients in Canada, Europe, South Africa, and the Middle East.
Since IDSI has yet to apply for premarket approval from the Food and Drug Administration for CTLM, the company must obtain an export certificate from the agency before it can ship the system. The certificate application must include letters from each country Cycle of Life Technologies services stating that the country will accept a non-FDA-approved device for import.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.